Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study

被引：0

作者：

Park, Wungki

O'Reilly, Eileen Mary

Furuse, Junji

Li, Chung-Pin

Oh, Do-Youn

Garcia-Carbonero, Rocio

Roth, Gael

Lee, Ho-Jin

Kunieda, Futoshi

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Kyorin Univ, Dept Med Oncol, Fac Med, Mitaka, Tokyo, Japan

[3] Taipei Vet Gen Hosp, Div Gastroenterol, Dept Med, Taipei, Taiwan

[4] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea

[5] 12 Octubre Univ Hosp, Madrid, Spain

[6] Univ Hosp Grenoble, Hepato Gastroenterol Dept, Grenoble, France

[7] Astellas Pharma Inc, Northbrook, IL USA

[8] Astellas Pharma Inc, Tokyo, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4186

引用

页数：1